Bonum Therapeutics Analysis: $93M Raised
What is Bonum Therapeutics?
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to disease-specific targets. The technology enables potent biological activity only at disease sites, reducing systemic toxicity. Two programs are in preclinical development, focused on enhancing anti-tumor immune responses in cancer treatment.
Location
Seattle, United States
Employees
11-50
Founded
2021
Funding Status
Series A
Product Features & Capabilities
- Antibody-regulated cytokine therapeutics
- Reversible activation mechanism
- Targeted delivery to disease sites
- Preclinical development of two cancer-focused programs
Use Cases
Activate cytokine therapy only in tumor microenvironments; Enhance anti-tumor immune response in solid tumors; Reduce systemic toxicity in cancer treatment; Target immune cells and tumor microenvironment components; Explore applications in autoimmune disease and metabolic disorders
Other Considerations
Two programs in preclinical development; Focused on cancer immunotherapy; Targets immune cells and tumor microenvironment; Reversible activation mechanism; Science-based approach with antibody-controlled activity
See something that needs updating? Suggest edits to this profile.